12 Analysts Have This to Say About HCA Healthcare

Within the last quarter, HCA Healthcare (NYSE:HCA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

Within the last quarter, HCA Healthcare (NYSE:HCA) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 6 2 0 0
Last 30D 0 1 0 0 0
1M Ago 4 3 2 0 0
2M Ago 0 2 0 0 0
3M Ago 0 0 0 0 0

According to 12 analyst offering 12-month price targets in the last 3 months, HCA Healthcare has an average price target of $284.17 with a high of $315.00 and a low of $254.00.

Below is a summary of how these 12 analysts rated HCA Healthcare over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 8.5% from the previous average price target of $310.56.

Stay up to date on HCA Healthcare analyst ratings.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Analyst Eyes Papa John’s Comparable Sales Amid Price-Value Concerns, Upgrades Stock To Hold

Stifel's Chris O'Cull shifts stance on Papa John's International to Hold, citing pragmatic near-term outlook. Despite lowering the price target to $60 amidst market turbulence, O'Cull emphasizes the stock's resilience. With -1% domestic comparable sales in Q1, challenges persist, particularly in a fiercely competitive market.

PZZA

Read More

Expert Ratings for ShockWave Medical

Over the past 3 months, 5 analysts have published their opinion on ShockWave Medical (NASDAQ:SWAV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

SWAV